Allarity Therapeutics Inc.

ALLR | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.17

-$0.04 (-3.31%)

At close: Sep 21, 2026, 4:00 PM ET

$1.18

+$0.01 (+0.85%)

Pre-market: Sep 22, 2026, 6:49 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-3.31%

(1D)

Rating

Updated: Aug 24, 2026

26.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $18.62M

1D Range

1.13 1.20

52W Range

0.77 1.84

Valuation (TTM)

PE -1.50

PB 5.26

EV/EBITDA -2.16

Valuation (NTM)

Forward PE N/A

Forward PEG -0.20

Price Target $11

Cash Flow

FCF Yield -74.0%

SBC Adj. FCF Yield -76.9%

SBC Impact -3.8%

Margins

Gross Margin 107.5%

Operating Margin -3129.0%

FCF Margin -3994.8%

Growth (CAGR)

Revenue 3Y | 5Y 150.0% | 100.0%

Dil EPS 3Y | 5Y 149.9% | 88.0%

FCF 3Y | 5Y 6.1% | 3.8%

Returns

ROA -38.4%

ROE -152.8%

ROIC -41.8%

Financial Health

Net Debt

$5.3M

Current Ratio 1.11

Interest Coverage -10.15

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific c...

Sector Healthcare

Industry Biotechnology

Employees 8

IPO Date Dec 20, 2021

Website www.allarity.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$11

Upside

+840.17%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞